Myasthenia Gravis

A case report highlights the benefits of applying patient-tailored therapies to mitigate the effects of neuromuscular immune-related adverse events and improve patient outcomes.

The therapy is already being evaluated in patients with lupus nephritis and diffuse cutaneous systemic sclerosis.

This new study sought to solidify a relationship between certain microbes in intestinal flora and the risk of developing myasthenia gravis, specifically those potentially reducing that risk.

Research presented at the 2023 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting emphasizes the potential need for patient support programs targeting at-risk populations to enhance disease management and reduce acute care utilization in myasthenia gravis.

When patients are undergoing treatment for cancer, clinicians should be aware of the potential to develop myasthenia gravis from immune checkpoint inhibitors (ICI), new research stresses, with ongoing surveillance and risk factor identification becoming necessary steps.

A retrospective study presented at the 2023 American Association of Neuromuscular and Electrodiagnotsic Medicine meeting revealed that social determinants of health (SDOH) are linked to poorer treatment outcomes in patients who have myasthenia gravis, emphasizing the need for identifying and supporting at-risk individuals.

Investigators evaluated the utility of the MG Symptoms Patient-Reported Outcome (PRO) within the armamentarium of instruments that currently evaluate myasthenia gravis (MG) severity.

This case report details an incident of pembrolizumab-induced myasthenia gravis in an elderly male patient being treated for urothelial cell bladder cancer.

With the approval, zilucoplan becomes the first once-daily subcutaneous complement C5 inhibitor available for adults with generalized myasthenia gravis.

A new analysis has determined potential risk factors for developing myasthenia gravis following COVID-19 vaccination, with symptoms likely to appear within 2 weeks of receipt of a COVID-19 vaccine.

Qualitative interviews were conducted and a web-based quantitative survey was administered to have a clearer understanding of the economic impact of social determinants of health on patients living with generalized myasthenia gravis (gMG).

Patients with generalized myasthenia gravis treated with efgartigimod consistently exceeded treatment compared with placebo regardless of gender in age, disease duration, body mass index, and thymectomy.

Overactivation of the immune system is a potential serious adverse event (AE) following immune checkpoint inhibition (ICI) treatment for any of several cancers in the first and second line; among these AEs is myasthenia gravis.

Approximately 70 to 300 million individuals worldwide are living with myasthenia gravis, an antibody-mediated autoimmune disorder that adversely affects neuromuscular junction function.

Patient acceptable symptom state (PASS) may be a reliable indicator of long-term outcomes among patients who have myasthenia gravis (MG).

The highest proportions of patients with severe ocular impairment at baseline showed greater improvements in symptom severity on ravulizumab in comparison with placebo after 26 weeks.

The investigation evaluated if symptom signatures of myasthenia gravis exacerbations could be evaluated using real-world data gathered via a smartphone-based research platform.

With this study, investigators hoped to describe personality traits among individuals who have the autoimmune, neuromuscular disease.

Investigators say computer algorithms can be used to assess physical and vocal signs of myasthenia gravis (MG).

This study compared autoantigen detection of acetylcholine receptor and muscle-specific kinase, among 3 assays used in suspected cases of myasthenia gravis.

Study authors used data from the Taiwan National Healthcare Insurance Research database and Death Registry for their population-based retrospective cohort study.

Nearly half of patients treated with zilucoplan were considered responders on Myasthenia Gravis Activities of Daily Living (MG-ADL) at the first week, suggesting a rapid onset of efficacy.

Investigators conducted a case study of a patient who presented with COVID-19–induced seronegative myasthenia gravis, seeking more information on neurological manifestations of the respiratory disease.

Lymphoplasmapheresis (LPE) was also completed with fewer replacements compared with plasma exchange (PE) for myasthenia gravis (MG).

The patient was found to have Toxoplasma gondii, a parasitic infection, and died 5 months after his initial diagnosis.